Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Yuhan licences lung cancer asset to Janssen in $1.25bn deal

pharmaceutical-technologyNovember 06, 2018

Tag: yuhan , Janssen , lung cancer , NSCLC , Lazertinib

PharmaSources Customer Service